SERUM PROSTATIC ACID-PHOSPHATASE, GAMMA-SEMINOPROTEIN AND PROSTATIC SPECIFIC ANTIGEN IN HEMODIALYSIS-PATIENTS

被引：20

作者：

SASAGAWA, I

NAKADA, T

HASHIMOTO, T

ISHIGOOKA, M

KUBOTA, Y

HIRANO, K

HIRANO, J

SUZUKI, Y

机构：

[1] Department of Urology, Yamagata University, School of Medicine, Yamagata

来源：

UROLOGIA INTERNATIONALIS | 1992年 / 48卷 / 02期

关键词：

PROSTATIC ACID PHOSPHATASE; GAMMA-SEMINOPROTEIN; PROSTATIC SPECIFIC ANTIGEN; HEMODIALYSIS;

D O I：

10.1159/000282326

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Serum concentrations of prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostatic specific antigen (PSA) were measured in 31 hemodialysis patients without clinical signs of malignant disease. PAP, gamma-Sm and PSA levels in serum were not significantly different between control and hemodialysis groups. A significant reduction in these tumor markers was not found after dialysis treatment. This indicates that the measurement of PAP, gamma-Sm and PSA in serum is useful for the detection of prostatic cancer in patients undergoing hemodialysis.

引用

页码：181 / 183

页数：3

共 16 条

[1]

Arai Y., Yoshiki T., Okada T., Et al., Multiple marker evaluation in prostatic cancer using prostatic specific antigen, gamma-scminoprotein and prostatic acid phosphatases, Urol Int, 44, pp. 135-140, (1989)

[2]

Kaplan J., Prestidgc B.R., Cox R.S., Et al., Prostatic specific antigen after irradiation for prostatic carcinoma, J Urol, 144, pp. 1172-1176, (1990)

[3]

Filella X., Cases A., Moline R., Et al., Tumor markers in patients with chronic renal failure, Int J Biol Markers, 5, pp. 85-88, (1990)

[4]

Kabalin J.N., Hornberger J.C., Prostatic specific antigen is not excreted by human kidney or eliminated by routine hemodialysis, Urology, 37, pp. 308-310, (1991)

[5]

Matas A.J., Simmonds R.L., Kjellstrand C.M., Et al., Increased incidence of malignancy during chronic renal failure, Lancet, 1, pp. 883-885, (1975)

[6]

Sasagawa I., Suzuki K., Ishizaki M., Et al., Prostatic cancer in a patient on long-term hemodialysis, Nephron, 59, pp. 506-507, (1991)

[7]

Dunnill M.S., Millard P.R., Oliver D., Acquired eystic disease of the kidneys. A hazard of long-term intermittent maintenance hemodialysis, J Clin Pathol, 30, pp. 868-877, (1977)

[8]

Goldblum S.E., Reed W.P., Host defenses and immunologic alterations associated with chronic hemodialysis, Ann Intern Med, 93, pp. 597-613, (1980)

[9]

Curtis J.R., Cancer and patients with end-stage renal failure, Br Med J, 284, pp. 69-70, (1982)

[10]

Lurie B.B., Loewenstein M.S., Zameheck N., Elevated circulating CEA levels in benign exlrahe-patic biliary tract obstruction and inflammation, JAMA, 233, pp. 326-330, (1975)

← 1 2 →